source
- Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidatesCavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…
- Tango and Revolution report high response rates in early pancreatic cancer combo trialTango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…